Abstract
The introduction of the drug-eluting stent (DES) has revolutionized the field of interventional cardiology during the past decade. Initial pivotal randomized clinical trials showed a large reduction in restenosis rates and the need for repeat intervention with DES compared with bare-metal stents. The three main components of a DES are 1) the stent platform, 2) a coating facilitating elution of the drug (mostly a polymer), and 3) a antiproliferative/anti-inflammatory drug. Currently, two classes of drugs are widely used in DES, Taxanes, including its best-known member Paclitaxel, and Rapamycins, which include Sirolimus and its analogues such as Everolimus, Zotarolimus and Biolimus A9. The first DES to receive United States Food and Drug Administration approval was the Sirolimus-eluting stent. Recently, two other stent types eluting a Sirolimus-analogue were approved; the Zotarolimus-eluting stent and the Everolimuseluting stent. Biolimus A9-eluting stents, using biodegradable polymers, are currently approved and marketed outside of the United States. This review article focusses on the clinical studies that have been performed with DES eluting Sirolimus or its analogues.
Keywords: Drug-eluting stents, Sirolimus, Rapamycin derivatives, Zotarolimus, Everolimus, Biolimus, drug-eluting stent (DES), restenosis rates, Taxanes, Paclitaxel, Rapamycins, Everolimus, Zotarolimus, Everolimuseluting, biodegradable polymers
Current Pharmaceutical Design
Title: Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems
Volume: 16 Issue: 36
Author(s): Bimmer E. Claessen, Jose P.S. Henriques and George D. Dangas
Affiliation:
Keywords: Drug-eluting stents, Sirolimus, Rapamycin derivatives, Zotarolimus, Everolimus, Biolimus, drug-eluting stent (DES), restenosis rates, Taxanes, Paclitaxel, Rapamycins, Everolimus, Zotarolimus, Everolimuseluting, biodegradable polymers
Abstract: The introduction of the drug-eluting stent (DES) has revolutionized the field of interventional cardiology during the past decade. Initial pivotal randomized clinical trials showed a large reduction in restenosis rates and the need for repeat intervention with DES compared with bare-metal stents. The three main components of a DES are 1) the stent platform, 2) a coating facilitating elution of the drug (mostly a polymer), and 3) a antiproliferative/anti-inflammatory drug. Currently, two classes of drugs are widely used in DES, Taxanes, including its best-known member Paclitaxel, and Rapamycins, which include Sirolimus and its analogues such as Everolimus, Zotarolimus and Biolimus A9. The first DES to receive United States Food and Drug Administration approval was the Sirolimus-eluting stent. Recently, two other stent types eluting a Sirolimus-analogue were approved; the Zotarolimus-eluting stent and the Everolimuseluting stent. Biolimus A9-eluting stents, using biodegradable polymers, are currently approved and marketed outside of the United States. This review article focusses on the clinical studies that have been performed with DES eluting Sirolimus or its analogues.
Export Options
About this article
Cite this article as:
E. Claessen Bimmer, P.S. Henriques Jose and D. Dangas George, Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454941
DOI https://dx.doi.org/10.2174/138161210794454941 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design and Screening Strategies for α-Glucosidase Inhibitors Based on Enzymological Information
Current Topics in Medicinal Chemistry Various Cell Therapy Approaches for Bone Diseases in the Controlled Clinical Trials: A Systematic Review and Meta-analysis Study
Current Stem Cell Research & Therapy Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Obesity-Induced Hypertension: New Insights
Current Pharmaceutical Design Polyphenols in Disease: from Diet to Supplements
Current Pharmaceutical Biotechnology The Promises and Challenges of the Use of Genomics in the Prescription of Exercise for Hypertension: The 2013 Update
Current Hypertension Reviews Nutrigenetics, Metabolic Syndrome Risk and Personalized Nutrition
Current Vascular Pharmacology A Systematic Review of Grand Multiparity
Current Women`s Health Reviews Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology Improving Health Care for Children with Chronic Conditions: Toward a “Wholistic” Approach
Current Pediatric Reviews Therapeutic Targeting of Chemokines with Monoclonal Antibodies
Current Immunology Reviews (Discontinued) GLP - 1 Analogs: Newer Molecules, Newer Uses
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Herbal Drug use in Sickle Cell Disease Management; Trends and Perspectives in Sub-Saharan Africa - A Systematic Review
Current Drug Discovery Technologies Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors
Current Neurovascular Research Do We Need More Research on Platelet Function in South Asian Immigrants?
Inflammation & Allergy - Drug Targets (Discontinued) Patents in Targets and Drugs for Insulin Resistance: Correlation with Inflammatory Mediators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Large Artery Stiffness and Antihypertensive Agents
Current Pharmaceutical Design Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Diabetic Medications in Pregnancy
Current Diabetes Reviews COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews